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Tinnitus is a common symptom, defined as a sound 
perception in absence of a sound stimulus. Aim: Evaluate 
if Trazodone, an antidepressant drug, which modulates 
serotonin at central neuronal pathways, is effective in 
controlling tinnitus. Study Design: Prospective, double 
blind, randomized, placebo-controlled. Materials and 
Methods: Study performed with patients presenting tinnitus. 
85 patients were analyzed between February and June of 
2005. 43 received trazodone and 42 placebo, for 60 days. The 
clinical criteria of analysis were tinnitus intensity, discomfort 
and life quality impact by tinnitus, using an analogue scale 
varying between 0 and 10, scored by patients before and 
after drug or placebo use. Results: There was a significant 
improvement in intensity, discomfort and life quality in both 
groups after treatment; however, there was no significant 
difference between the drug and placebo groups. Patients 
with age equal or over 60 years presented better results 
after treatment. Conclusion: Trazodone was not efficient 
in controlling tinnitus in the patients evaluated under the 
doses utilized.
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INTRODUCTION
Tinnitus is a frequent symptom in our clinical 
practice, it happens alone, or in combination with other 
systemic or otologic diseases. It is defined as an auditory 
sound perception in the absence of a generated sound 
stimulus, occurring from a failure in the auditory system 
(central and/or peripheral), encompassing the auditory 
sound masking1,2.
Tinnitus is related to a number of structures of 
the central nervous system, and to find out the role of 
each of these structures is one of the major challenges 
associated with treatment3,4. The most recent hypothesis 
used to explain its genesis and maintenance is based on 
the existence of a final common auditory pathway, and 
tinnitus would represent a failure caused by a lesion or 
inadequate workings at some point in this pathway, invol-
ving anatomical sites and neurotransmitters1,5,6. Auditory 
pathways are, in reality, a vast network of interconnected 
cells, from the cochlear external hair cells all the way to 
the temporal lobe, modulated by neurotransmitters such 
as dopamine, serotonin, GABA and glutamate, responsible 
for sound detection, location and interpretation6,7.
Current evidences show that serotonin is able to 
modulate neuronal activity and the plasticity of the cen-
tral pathways; therefore, altered serotonin levels in these 
sensorial pathways and alterations in the workings of its 
receptors could cause different auditory disorders, tinni-
tus among them. Thus, serotonin is currently seen as one 
of the most important neurotransmitters involved in the 
genesis and maintenance of this symptom8,9.
This cellular and molecular knowledge points to-
wards new treatment and approach possibilities insofar 
as tinnitus is concerned. Studies involving medication 
that promote proper serotonin availability in the auditory 
pathways could have a positive impact in the treatment 
of tinnitus caused by inadequate functioning of central 
auditory pathways, facilitating synaptic conduction and 
organization, as well as the modulating action within au-
ditory inhibitory systems (efferent pathways). 
Trazodone is a drug classified among a group of 
antidepressant medication, being considered an atypical 
antidepressant agent, a derivative of triazolpyridine. Its 
molecule does not bear association with the other drugs 
of similar effect, thus being different from the other drugs 
of this group because it has a specific chemical structure 
and it promotes, besides serotonin reuptake pre-synaptic 
inhibition (like the other medication in this group), it 
blocks 5-HT2A e 5-HT2C serotonin receptors in the post-
neuronal synapses. 10. Thus, it bears a double mechanism 
of action for the increase in the serotonin levels in the 
central auditory pathway synapses.
Trazodone is clinically indicated for the treatment 
of depression, and sleep psychiatric disorders. It bears 
minimum anticholinergic activity, providing greater safe-
ty for the geriatric population10. The most frequent side 
effects are sleepiness, sedation and hypotension; and 
less frequently: dry mouth, gastrointestinal discomfort, 
dizziness, headache and hypertension. There may rarely 
be priapism, thus it may be used in patients with erectile 
dysfunction11,13.
Throughout this medication action mechanism we 
could supposedly promote tinnitus symptom improvement 
in our patients. Thus, it seemed to us very pertinent to carry 
out a clinical trial to measure this possible action.
OBJECTIVE
Our goal with the present investigation is to assess 
whether Trazodone acts positively in tinnitus control.
MATERIALS AND METHODS
This is a prospective, double blind, randomized 
and placebo-controlled study with patients complaining 
of tinnitus. This research project was analyzed and appro-
ved by the Research Ethics Committee, under protocol # 
1246/04.
The group of tinnitus patients added up to 104 
individuals, complying with the following study inclusion 
criteria:
 
Inclusion Criteria:
• Age between 45 and 80 years.
• Both genders.
• Tinnitus with maximum progression time of one 
year.
• Patients with normal audiograms and mild to 
moderate sensorineural hearing loss.
• No defined-etiology diseases in the middle ear.
• Contra-indication regarding the use of Trazodo-
ne.
• Signature in the Informed Consent Form and 
Patient’s Information Letter, after being duly educated.
 
Exclusion Criteria:
• External and middle ear diseases or altered 
otoscopy.
• Conductive and mixed hearing loss.
• Severe/Profound sensorineural hearing loss.
• Use of other medication that could impact tin-
nitus.
• Concomitant use of other Serotonin reuptake 
inhibition drug or other that may act on central neuro-
transmitters.
• Prior use of Trazodone.
 A total of 104 patients were assessed between Fe-
bruary and June of 2005.  Of the 85 who remained in the 
study until the end, 43 patients received the medication 
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and 42 received placebo. 
Prior to the use of the drug or placebo, we carried 
out tonal and vocal audiometry and impedanciometry. 
The medication was used in the dose of 50mg per tablet, 
through a single night dose for 60 continuous days. If 
important side effects were seen, the medication was 
discontinued. 
Clinical analysis criteria were intensity, life quality 
impact and level of discomfort caused by tinnitus, by me-
ans of using an analogue scale with scores from 0 to 10 
given by the patient before and after using trazodone or 
placebo. We compared the relationship between audio-
gram profile, gender, age equal to or above 60 years and 
intensity level before treatment and the analysis criteria.
We assessed whether tinnitus intensity levels hi-
gher or lower before treatment had any association with 
tinnitus intensity after treatment. For that we created the 
intensity difference variable (final intensity minus the initial 
intensity). We then calculated the Pearson’s correlation 
coefficient with the pre-treatment intensity and we could 
then check to see if the higher or lower difference had 
any association with the higher or lower tinnitus intensity 
before treatment.
The tablets (drug and placebo) were similar in 
shape, color and size, identified only by the numbers “23” 
and “24” by the pharmaceutical company that provided 
the medication. Only the pharmacist knew what drug was 
being given to which patient until the end of drug use and 
the clinical evaluation of the patients. 
At the end of the study we learned that medication 
number “23” was the active drug (Trazodone) and the 
number “24” was the placebo.
We used the ANOVA (variance analysis), chi-squa-
red and t-independent statistical methodologies to analyze 
the data obtained. 5% was the test significance level, and 
the data were deemed significant when p was less than 
or equal to 0.05.
RESULTS
The groups were homogeneous in gender, tinnitus 
dwelling time, form of onset, frequency and audiometric 
profile.
The results obtained and the group of patients 
evaluated in our study is presented in tables. We evalu-
ated 25 women (58.1%) and 18 men (41.9%) who used 
Trazodone; and 31 women (73.8%) and 11 men (26.2%) 
with placebo.
As to how frequent the patients had tinnitus, we 
assessed 36 patients (83.7%) with continuous tinnitus and 
7 with intermittent tinnitus who used trazodone, and 37 
patients (88.1%) with continuous tinnitus, 5 intermittent 
(11.9%) used placebo.
The groups were homogeneous (p=0.69). In both 
groups there was improvement after medication use 
(p<0.0001); however, there was no statistically signifi-
cant difference between the drug and placebo groups 
(p=0.59).
The groups were homogeneous (p=0.10). In both 
groups there was improvement after medication use 
(p<0.0001); however, there was no statistically significant 
difference between the drug and placebo groups (p=0.41). 
There was an indication that the drug was associated with 
greater discomfort.
Table 1. Tinnitus dwelling time in years for the patients evaluated in 
this study.
 Drug Placebo
Mean value 6.07 6.55
Standard deviation 5.05 6.83
N 43 42
Test t (p) = 0.715
Table 2. Tinnitus onset in the patients evaluated in this study.
 Drug Placebo
 N % N %
Gradual 33 76.7 31 73.8
Sudden 10 23.3 11 26.2
Total 43 100.0 42 100.0
Chi-squared test (p) = 0.754
Table 3. Audiometric profile of the patients evaluated in this study.
 GROUP
Total
 Drug Placebo
 N % N % N %
Mild 17 39,5% 16 38% 33 38,8%
Mode-
rate
11 25,5% 14 33,4% 25 29,4%
Normal 15  35% 12 28,6% 27 31,8%
Total 43 100,0% 42 100,0% 85 100,0%
Table 4. Tinnitus intensity as reported by the patients before and 
after treatment - mean values, standard deviations and variance 
analysis.
  Initial Post
 Mean value 6,60 5,86
Drug Standard deviation 1,59 2,33
 N 43 43
 Mean value 6,55 5,62
Placebo Standard deviation 1,60 2,08
 N 42 42
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The groups were homogeneous (p=0.26). In both 
groups there was an improvement after medication use 
(p<0.0001); however, there was no statistical difference 
between the drug and placebo groups (p=0.77).
groups there was improvement after medication use 
(p<0.0001); however, there was no statistical difference 
between drug and placebo (p=0.58).
 Therefore, there was no relation between the au-
diometric profile and intensity, discomfort and life quality 
impact before and after treatment.
Table 5. Level of discomfort caused by the tinnitus before and after 
treatment - mean values, standard deviations and variance analysis.
  Initial Post
 Mean value 6,56 5,91
Drug Standard deviation 1,86 2,50
 N 43 43
 Mean value 6,02 5,10
Placebo Standard deviation 1,70 1,96
 N 42 42
Table 6. Tinnitus impact on the patients’ life quality before and after 
treatment - mean values, standard deviations and variance analysis.
  Initial Post
 Mean value 6,12 5,49
Drug Standard deviation 1,82 2,39
 N 43 43
 Mean value 5,71 5,00
Placebo Standard deviation 1,66 1,96
 N 42 42
Table 7. Tinnitus intensity reported by the patients before and after 
treatment according to their hearing levels - mean values, standard 
deviations and variance analysis.
  Normal Mild Moderate
  
Ini-
tial
Post
Ini-
tial
Post
Ini-
tial
Post
 Mean value 6,87 5,93 6,82 6,12 5,91 5,36
Drug
Standard 
deviation
1,46 2,69 1,55 1,87 1,76 2,58
 N 15 15 17 17 11 11
 Mean value 6,58 6,08 6,44 5,50 6,64 5,36
Placebo
Standard 
deviation
1,38 1,24 1,71 2,28 1,74 2,47
 N 12 12 16 16 14 14
The groups were homogeneous (p=0.86). Both 
groups improved after medication (p<0.0001); however, 
there was no statistical difference between the drug and 
placebo groups (p=0.41).
The groups were homogeneous (p=0.14). In both 
groups there was an improvement after the use of medi-
cation (p<0.0001); however, there were no statistical diffe-
rence between the drug and placebo groups (p=0.31).
The groups were homogeneous (p=0.35). In both 
Table 8. Level of discomfort caused by tinnitus reported by the pa-
tients before and after treatment, according with their hearing levels 
- mean values, standard deviations and variance analysis.
  Normal Mild Moderate
  Initial Post Initial Post Initial Post
 
Mean 
value
6,60 5,80 6,82 6,18 6,09 5,64
Drug
Standard 
deviation
1,64 2,65 1,59 1,88 2,51 3,23
 N 15 15 17 17 11 11
 
Mean 
value
5,92 5,58 6,25 4,88 5,86 4,93
Placebo
Standard 
deviation
1,68 1,51 1,57 2,16 1,96 2,13
 N 12 12 16 16 14 14
Table 9. Tinnitus impact on the patient’s life quality before and after 
treatment according to hearing levels - mean values, standard devia-
tions and variance analysis.
  Normal Mild Moderate
  Initial Post Initial Post Initial Post
 
Mean 
value
6,20 5,60 6,41 5,65 5,55 5,09
Drug
Standard 
deviation
1,57 2,38 1,66 2,06 2,34 3,02
 N 15 15 17 17 11 11
 
Mean 
value
5,67 5,42 5,88 5,00 5,57 4,64
Placebo
Standard 
deviation
1,37 1,31 1,63 2,07 1,99 2,34
 N 12 12 16 16 14 14
Table 10. Tinnitus intensity reported by the patients before and after 
treatment, broken down by gender, in terms of mean values, stan-
dard deviations and variance analysis.
  Drug Placebo
  Initial Final Initial Final
 Mean value 6,84 6,04 6,58 5,55
Females
Standard 
deviation
1,60 2,35 1,57 2,10
 N 25 25 31 31
 Mean value 6,28 5,61 6,45 5,82
Males
Standard 
deviation
1,56 2,33 1,75 2,14
 N 18 18 11 11
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The groups were homogeneous (p=0.82). In both 
groups there was an improvement after the use of medi-
cation (p<0.0001); however, there was no statistical diffe-
rence between the placebo and drug groups (p=0.72).
patients when we compared trazodone and placebo. 
There were no statistically significant differences in 
relation to hearing loss being present or not, and in both 
Table 11. Tinnitus-caused level of discomfort reported by the pa-
tients before and after treatment, according to gender - mean values, 
standard deviations and variance analysis.
  Drug Placebo
  Initial Final Initial Final
 Mean value 6,76 6,08 6,13 5,06
Females
Standard 
deviation
1,74 2,45 1,78 2,03
 N 25 25 31 31
 Mean value 6,28 5,67 5,73 5,18
Males
Standard 
deviation
2,02 2,61 1,49 1,83
 N 18 18 11 11
The groups were homogeneous (p=0.82). In both 
groups there was an improvement after medication use 
(p<0.0001); however, there were no statistically signifi-
cant differences between the drug and placebo groups 
(p=0.72).
Table 12. Life quality impact of tinnitus before and after treatment 
broken down by gender - mean values, standard deviations and 
variance analysis.
  Drug Placebo
  Initial Final Initial Final
 Mean value 6,36 5,68 5,77 4,97
Females
Standard 
deviation
1,66 2,36 1,65 1,94
 N 25 25 31 31
 Mean value 5,78 5,22 5,55 5,09
Males
Standard 
deviation
2,02 2,49 1,75 2,12
 N 18 18 11 11
The groups were homogeneous (p=0.34). In both 
groups there was improvement after medication use 
(p<0.0001); however, there was no statistically signifi-
cant difference between the drug and placebo groups 
(p=0.73).
Therefore, there was no association between gender 
and the responses regarding intensity, discomfort and life 
quality impact before and after treatment. 
We assessed if the higher or lower tinnitus intensity 
levels before treatment had any association with the tinni-
tus intensity improvement after treatment, and we obtained 
the Pearson’s correlation index of -0.024 (p=0.825).
Table 13. Association between age equal to or less then 60 years 
and tinnitus intensity before and after treatment - mean values, stan-
dard deviations and variance analysis.
  Drug Placebo
  Initial Final Initial Final
 Mean value 7,00 6,35 7,00 6,86
< 60 years
Standard 
deviation
1,41 2,23 1,24 1,41
 N 26 26 14 14
 Mean value 6,00 5,12 6,32 5,00
>= 60 
years
Standard 
deviation
1,70 2,34 1,72 2,11
 N 17 17 28 28
Table 14. Association between age equal to or higher than 60 years 
and tinnitus-related discomfort reported by the patients before and 
after treatment - mean values, standard deviations and variance 
analysis.
  Drug Placebo
  Initial Final Initial Final
 Mean value 6,88 6,27 6,29 6,07
< 60 years
Standard 
deviation
1,58 2,25 1,14 1,33
 N 26 26 14 14
 Mean value 6,06 5,35 5,89 4,61
>= 60 
years
Standard 
deviation
2,16 2,80 1,93 2,06
 N 17 17 28 28
There was no significance and, therefore, no relation 
between the tinnitus initial intensity level and after-treat-
ment improvement.
 The groups were homogeneous (p=0.63). In both 
groups there was improvement after treatment (p<0.0001), 
and the group with age equal to or higher then 60 ye-
ars presented with less intensity tinnitus after treatment 
(p=0.04).
The groups were homogeneous (p=0.30). In both 
groups there was improvement after treatment (p<0.0001), 
and the group with age above or equal to 60 years pre-
sented less tinnitus-related discomfort after treatment 
(p=0.09).
The groups were homogeneous (p=0.68). In both 
groups there was improvement after treatment (p<0.0001), 
and the group with age equal to or higher then 60 years 
presented the least tinnitus-related impact on life quality 
after treatment (p=0.08).
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Table 15. Association between age equal to or higher then 60 years 
and the tinnitus-caused impact on life quality reported by the pa-
tients before and after treatment - mean values, standard deviations 
and variance analysis.
  Drug Placebo
  Initial Final Initial Final
 Mean value 6,58 6,00 6,00 5,93
< 60 years
Standard 
deviation
1,63 2,24 1,24 1,33
 N 26 26 14 14
 Mean value 5,41 4,71 5,57 4,54
>= 60 
years
Standard 
deviation
1,91 2,47 1,83 2,08
 N 17 17 28 28
Table 16. Adverse effects the patients in the study presented. 
 GROUP
Total
 D P
 N % N % N %
No adver-
se effects 
36 83,7% 39 92,9% 75 88,2%
Apathy 1 2,3% 0 0,0% 1 1,2%
Sour 
mouth
0 0,0% 1 2,4% 1 1,2%
Hyperten-
sive crisis
1 2,3% 0 0,0% 1 1,2%
Epigas-
tralgia
1 2,3% 0 0,0% 1 1,2%
Insomnia 0 0,0% 1 2,4% 1 1,2%
Nausea 1 2,3% 0 0,0% 1 1,2%
Sleepi-
ness
3 7,0% 1 2,4% 4 4,7%
Total 43 100,0% 42 100,0% 85 100,0%
The statistical test was not used because of the low incidence of 
side effects presented by the patients. 
The age range of age equal to or higher than 60 
years presented less values of intensity, discomfort and 
life quality impact after treatment. There was a greater 
reduction of such factors in the placebo group.
The statistical test was not used because of the low 
incidence of side effects presented by the patients. 
The statistical test was not used because of the low 
incidence of side effects presented by the patients. 
Table 17. Other improvements reported by the patients who partici-
pated in the study.
 GROUP
Total
 Drug Placebo
 N % N % N %
Not reported 35 81,4% 40 95,2% 75 88,2%
Irritability 
reduction
2 4,7% 0 0,0% 2 2,4%
Improve in 
sleep
6 14,0% 2 4,8% 8 9,4%
Total 43 100,0% 42 100,0% 85 100,0%
The statistical test was not used because of the low incidence of 
side effects presented by the patients. 
DISCUSSION
Where tinnitus is concerned, there are a number 
of neurotransmitters acting in the central pathways and 
interacting among themselves, it may be for this reason 
that we do not find positive results acting in the modu-
lation of one neurotransmitter only, and also for the fact 
that there may be other anatomical sites involved in the 
genesis and maintenance of tinnitus8,9, and the lack of 
proven efficient methods to detect where in the central 
auditory pathway is the tinnitus triggering point3,4,14. It is 
very likely that in order to control this symptom, we will 
need to develop drugs that act on the many anatomical 
sites and also methods to locate the specific site respon-
sible for the genesis and maintenance of tinnitus in the 
central auditory pathways.
Another very important fact is the need to approach 
these patients in the acute phase (early on) of tinnitus 
onset, before it centralizes, preventing plastic changes 
to occur in the central nervous system, causing tinnitus 
chronification8. This explains why, in the acute phase, 
tinnitus is more easily treated and with better clinical 
outcome. When it becomes chronic, the patient loses the 
habituation mechanism15 and, consequently, treatment 
becomes complex because of central alterations.
Psychological and psychiatric factors are often times 
present in tinnitus patients, that triggers or accruing from it, 
are greatly relevant, and this alone would justify treatment 
with antidepressant agents16,17,18. Thus, satisfactory results 
corroborate a double mechanism for tinnitus improvement 
in these patients, in other words, acting on the neurotrans-
mitters of the central auditory pathway receptors and on 
psychogenic/depression factors19,20,21. There are reports of 
tinnitus onset or return in patients under use of antide-
pressant medication when it was discontinued because of 
improvements in the depression22,23.
In our study we did not find significant improve-
ments in tinnitus intensity and life quality among these 
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cases there was not improvement in tinnitus intensity, 
discomfort and life quality before and after the use of 
these agents.
This tells us that the patient having or not having 
hearing loss did not have any positive influence in tinnitus 
improvement with the use of trazodone.
Comparing gender and improvement before and 
after the use of the drug or placebo, we did not find any 
significance. We then inferred that gender, despite the 
fact that tinnitus is more prevalent in females, does not 
represent a predictive factor for improvement.
Prior tinnitus intensity did not contribute to treat-
ment improvement, as shown by the Pearson’s correlation 
coefficient, probably because of tinnitus centralization and 
chronification, regardless of level of intensity.
When we analyzed the relationship between pa-
tients with ages equal to or above 60 years and tinnitus 
intensity improvement, discomfort and life quality impact 
before and after treatment, we noticed significance for 
them in this age range, with a greater reduction in these 
factors, particularly in the placebo group. This may indi-
cate that in elderly patients, antidepressant medication 
may improve tinnitus, especially in the placebo group. 
This may indicate that in the elderly patients, antidepres-
sants may improve tinnitus, especially because depressive 
symptoms are more frequent in this age range, and also 
because of the good doctor-patient relationship, which 
could also explain a greater improvement in the patients of 
the placebo group, by giving the patient attention, advice, 
clearing up doubts and answering the patient’s questions 
regarding their tinnitus. 
It was interesting to hear some patients complaining 
of sleepiness after using trazodone, reported as a desirable 
effect, because they started to sleep better, having less 
sensation of tinnitus at night, when usually the patients 
complain more of this symptom. Other patients reported 
it as an undesirable effect, because it affected their daily 
activities11. There was a small incidence of important ad-
verse effects, and it was necessary to discontinue the treat-
ment in one patient, who had a hypertension crisis on the 
third day of trazodone, very likely medication-related.
The initial dose used was 50 to 150mg/day, divided 
in two doses or in a single daily dose taken at night10,11,12. 
It may be that by using higher trazodone doses (100 
to 150 mg/day), as the doses used to treat depression, 
more satisfactory results could be attained, since tinnitus 
happens because of alterations in the activities of neuro-
transmitters and their receptors. Thus, there would be a 
more pronounced improvement of this symptom due to 
a greater availability of serotonin in the central auditory 
pathways, because of a greater block of its post-synaptic 
receptors12,24.
This study was important in order to identify that, 
low medication doses that act on serotonin modulation in 
the central auditory pathway synapses may not be efficient 
in improving clinical signs and symptoms, despite mini-
mum side effects. Prolonged use, in higher doses, could 
improve even further the tinnitus discomfort; however, 
severe side effects and medication addiction are relevant 
facts that should be considered.
Further studies on the central auditory pathways’ 
neurotransmitters are necessary in order to better explain 
the role of each one in the genesis and maintenance of 
tinnitus, so that we may provide our patients with a better 
therapeutic approach. 
CONCLUSION
In the dose used, trazodone was not efficient in 
controlling tinnitus for our group of patients.
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